Sphingosine kinase inhibitors
USRE49811E1 · kind E1 · reissue
0Cited by
12References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2022 |
| Grant date | Jan 23, 2024 |
| Priority date | — |
| Expiry date | Mar 7, 2042 |
Classification
- Technology area (CPC —)General
Abstract
The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.